STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] NeoGenomics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Neogenomics, Inc. Schedule 13G discloses that First Light Asset Management, LLC beneficially holds 9,544,749 shares of Neogenomics common stock (about 7.39% of the class). Mathew P. Arens is reported as beneficial owner of 9,784,749 shares (about 7.57%), which reflects his control of the manager plus 100,000 shares held directly and additional shares held jointly. The filing is submitted under Rule 13d-1(b), indicating these holdings are reported as passive and not intended to change or influence control of the issuer. The filing includes a joint filing agreement and identifies the reporting persons' business address.

Positive
  • Significant disclosed stake: First Light Asset Management holds 9,544,749 shares (7.39%), which is a meaningful minority position
  • Controller disclosure: Mathew P. Arens is reported with 9,784,749 shares (7.57%), clarifying beneficial ownership and control relationships
  • Filed as passive: Reported under Rule 13d-1(b), indicating holdings are stated as held in the ordinary course and not for control
Negative
  • None.

Insights

TL;DR: A passive investor and its controlling individual report just over 7% ownership each, a meaningful minority stake but not an activist position.

First Light Asset Management reports beneficial ownership of 9,544,749 shares (7.39%), while Mathew P. Arens is reported at 9,784,749 shares (7.57%). The Schedule 13G was filed under Rule 13d-1(b), which signals the positions are held in the ordinary course of business and not for control purposes. For investors, a >5% passive stake is material because it signals a substantial, visible shareholder, yet the classification as passive reduces near-term governance change risk. No transaction amounts, purchase dates, or voting changes are disclosed.

TL;DR: Reported holdings represent a significant minority interest but are explicitly characterized as non-control, limiting immediate governance implications.

The filing identifies First Light as advisor to accounts and funds holding 9,544,749 shares, and Mr. Arens as controller of the manager plus direct and joint holdings totaling 9,784,749 shares. TheSchedule 13G classification under Rule 13d-1(b) means the reporting parties certify the shares are not held to influence control. This reduces the likelihood of imminent board or strategic demands, though investors should note the size of the stake when assessing shareholder composition. The filing provides no indications of planned activism or board nominations.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



First Light Asset Management, LLC
Signature:/s/ Kurt T. Peterson
Name/Title:Kurt T. Peterson/Chief Compliance Officer
Date:08/14/2025
Mathew P. Arens
Signature:/s/ Mathew P. Arens
Name/Title:Mathew P. Arens/Chief Executive Officer
Date:08/14/2025
Exhibit Information

Exhibit A: Joint Filing Agreement

FAQ

What stake does First Light Asset Management hold in Neogenomics (NEO)?

First Light Asset Management is reported to beneficially own 9,544,749 shares, representing 7.39% of Neogenomics' common stock.

How many Neogenomics shares does Mathew P. Arens beneficially own?

Mathew P. Arens is reported to beneficially own 9,784,749 shares, representing 7.57% of the class, including 100,000 shares held directly.

Did the filing state the holdings are intended to influence control of NEO?

No. The Schedule 13G is filed under Rule 13d-1(b), and the reporting persons certify the shares are held in the ordinary course and not to change or influence control.

Where is First Light Asset Management located per the filing?

The reporting persons list their principal business office at 3300 Edinborough Way, Suite 201, Edina, MN 55435.

Does the filing indicate any transaction amounts or acquisition dates for the shares?

No. The Schedule 13G discloses current beneficial ownership and classification as passive but does not provide purchase amounts or acquisition dates.
Neogenomics Inc

NASDAQ:NEO

NEO Rankings

NEO Latest News

NEO Latest SEC Filings

NEO Stock Data

1.37B
127.72M
1.29%
100.33%
4.05%
Diagnostics & Research
Services-testing Laboratories
Link
United States
FORT MYERS